Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study

Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study

Podrobná bibliografie
Hlavní autoři: Kappos, L, Comi, G, Palace, J, Siever, A, Marrosu, M, Mehling, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Gold, R
Médium: Conference item
Vydáno: 2012

Podobné jednotky